MAP2K7 and melanoma: Furthermore, the POLARIS phase II study (ClinicalTrials.gov identifier: NCT03911869) evaluated the combination of encorafenib and binimetinib in patients with BRAFV600-mutant melanoma and asymptomatic brain metastases who had not previously received BRAF/MEK inhibitors.